黑料网

Blindness due to diabetic retinopathy has grown to be a serious worry for all those involved in the care of diabetic ESRD patients concurrently with the pandemic expansion of diabetes as the primary cause of the condition. Macular edoema and proliferative retinopathy can contribute to vision loss. A cohort of five diabetic people who were taken from a study of erythropoietin-treated azotemic anaemic preESRD patients had their renal function, blood rheology, and the progression of diabetic eye disease reevaluated. Ophthalmologists and nephrologists work together as cotherapists to treat what has been called the diabetic renal-retinal condition due to the amazing success of laser photocoagulation in preventing irreversible vision loss in diabetes. Reduction of the chance of blindness by contemporary interventional laser surgery has been astounding [1]. For instance, a retinal screening programme has been in place in the Newcastle District of the United Kingdom since, and there, "the rates of blindness and partialsightedness are less than one-third of those reported in surveys previous to In this study, we provide our mostly anecdotal and observational experiences evaluating how eye illness responded to erythropoietin treatment in a pilot sample of anaemic, azotemic diabetic patients. The renal clinic at University Hospital of Brooklyn was asked for volunteers to participate in a study looking at how erythropoietin affects anaemia caused by renal insufficiency [2]. The Institutional Review Board gave their approval to the project. Every participant provided written informed permission. Adult participants, including diabetics. Who had anaemia related to renal insufficiency were given erythropoietin after normal iron levels were confirmed. The lack of gastrointestinal and urinary blood loss, anaemia caused by conditions other than kidney disease, and a serum creatinine concentration between were inclusion criteria. Patients with diabetes were accepted for the trial [3]. Absence of concurrent conditions likely to progress to a life-threatening degree within a year was one of the exclusion criteria. Five diabetic patients met the admission requirements out of the 40 people who were involved in the trial [4]. These five diabetic participants' anaemia was affected by erythropoietin in a previous presentation that was partially unreviewed. The evaluation of erythropoietin's impact on macular edoema in the three individuals listed below has already been partially described. Each diabetic participant underwent a physical examination, the measurement of seated blood pressure, an electrocardiogram, an ophthalmologic evaluation involving retinal photography and, when required, fluorescein angiography of the retina. Patients were monitored ambulatorily at intervals ranging from weekly to monthly, depending on their condition and complications. A physical examination, which included taking sitting blood pressure, was done at each visit, along with getting a hemogram and a chemical screen [5]. The trial's endpoints were either mortality or progression to end-stage renal disease. Ortho Pharmaceutical Corporation provided erythropoietin, which was manufactured by Amgen Corporation. Continuation of drugs was done as the primary nephrologist deemed necessary. Multiple daily finger-stick glucose tests in conjunction with fractional insulin doses or oral hypoglycemic medications were used to provide the best metabolic control of hyperglycemia. As described by Wells et al., the Wells-Brookfield cone plate viscometer at Brookfield Engineering Laboratories, Stoughton, was used to measure the viscosity of an aliquot of heparinized venous whole blood or plasma. Every measurement was performed twice. Daily checks of the viscosity of standard fluids provided by Brook-field Engineering Laboratories (with viscosities in the range of human blood) and distilled water were done to ensure that the instruments were accurate and precise. Following venesection, all measures were taken within two hours. in order to compare to a control. One ophthalmologist examined the group of three diabetic ladies who had macular edoema. The progression of their macular edoema is documented here in retrospective rather than prospective fashion, reflecting a clinical experience [6]. The statistical analysis of treatment groups was not done because there were no concurrent control groups and there were only five azotemic diabetics in each group, including three people with macular edoema. Pre- and post-erythropoietin levels in five predialysis azotemic diabetic patients were compared. On three diabetic participants who had macular edoema and anaemia, the beneficial effects of erythropoietin treatment are detailed. One theory for the beneficial effects of a higher hematocrit on diabetic nephropathy and retinopathy is that the metabolic, hormonal, and hemodynamic elements of the diabetic syndrome work together to produce tissue and cellular hypoxia, which is partially alleviated by a higher red cell mass's increased ability to transport oxygen. Diabetes' pseudohypoxia may have a role in the development of diabetic neuropathy, retinopathy, muscular dystrophy, and nephropathy. Nitric oxide causes oxidative stress in the angiogenic process that underlies proliferative diabetic retinopathy and macular edoema, together with its stable end products nitrite and nitrate. The levels of NO and vascular endothelial growth factor are noticeably greater than Erythropoietin administration to anaemic diabetic subjects cannot be justified by a complete lack of this hormone. We stress that our conclusions cannot be compared to an untreated population of diabetic patients who are consistently anaemic and azotemic, since they would now represent unethical nephrology practise.

1. Seliger S, Fox KM, Gandra SR, Bradbury B, Hsu VD et al. (2010) Clin J Am Soc Nephrol 5:882-888.

, ,

2. Theurl I, Schroll A, Sonnweber T, Nairz M, Theurl M et al. (2011) Blood 118: 4977-4984,

, ,

3. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G et al. (2009) Clin J Am Soc Nephrol 4: 1051-1056.

, ,

4. Björck S, Mulec H, Johnsen SA, Norden G, Aurell M et al. (1992) Br Med J 304: 339-343

, ,

5. Patel V, Rassam S, Newsom R (1992) . BMJ 305: 678-83.

, ,

6. Patel JI, Hykin PG, Cree IA (2006) Br J Ophthalmol 90:697-701.

, ,